[go: up one dir, main page]

MX2012013362A - Una composicion farmaceutica de liberacion controlada de losartan. - Google Patents

Una composicion farmaceutica de liberacion controlada de losartan.

Info

Publication number
MX2012013362A
MX2012013362A MX2012013362A MX2012013362A MX2012013362A MX 2012013362 A MX2012013362 A MX 2012013362A MX 2012013362 A MX2012013362 A MX 2012013362A MX 2012013362 A MX2012013362 A MX 2012013362A MX 2012013362 A MX2012013362 A MX 2012013362A
Authority
MX
Mexico
Prior art keywords
losartan
controlled release
release composition
pharmaceutical controlled
prophylaxis
Prior art date
Application number
MX2012013362A
Other languages
English (en)
Inventor
Antonio Sereno Guerra
David Loeches Blas
Roberto Varas Fernandez-Molina
Estibaliz Del Cura Medina
Jose Miguel Rizo Martinez
Original Assignee
Liconsa Laboratorios Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liconsa Laboratorios Sa filed Critical Liconsa Laboratorios Sa
Publication of MX2012013362A publication Critical patent/MX2012013362A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de liberación controlada de losartan que comprende un núcleo de retención gástrica con losartan y una cantidad comprendida entre 5 y 25% en peso de hidroxipropilmetilcelulosa como único polímero de liberación controlada, y una capa activa de liberación inmediata que contiene losartan, a su procedimiento de preparación y a su uso para la profilaxis y el tratamiento de la hipertensión.
MX2012013362A 2010-05-21 2011-05-20 Una composicion farmaceutica de liberacion controlada de losartan. MX2012013362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382135A EP2392318A1 (en) 2010-05-21 2010-05-21 A pharmaceutical controlled release composition of losartan
PCT/EP2011/058229 WO2011144724A1 (en) 2010-05-21 2011-05-20 A pharmaceutical controlled release composition of losartan

Publications (1)

Publication Number Publication Date
MX2012013362A true MX2012013362A (es) 2013-05-01

Family

ID=42635468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013362A MX2012013362A (es) 2010-05-21 2011-05-20 Una composicion farmaceutica de liberacion controlada de losartan.

Country Status (7)

Country Link
EP (2) EP2392318A1 (es)
AR (1) AR081400A1 (es)
BR (1) BR112012029565A2 (es)
MX (1) MX2012013362A (es)
TW (1) TW201201800A (es)
UY (1) UY33393A (es)
WO (1) WO2011144724A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002673A1 (en) * 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN119112811A (zh) * 2016-08-29 2024-12-13 北京科信聚润医药科技有限公司 一种氢氯噻嗪微片及其制备方法
IT201800011123A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione cronotropica di sartani

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
EP2086519B1 (en) * 2006-10-30 2017-06-21 HanAll Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
WO2011144724A1 (en) 2011-11-24
TW201201800A (en) 2012-01-16
AR081400A1 (es) 2012-08-29
BR112012029565A2 (pt) 2016-12-13
EP2571495A1 (en) 2013-03-27
UY33393A (es) 2011-12-30
EP2392318A1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2011012993A (es) Bencimidazoles, benzotiazoles y benzoxazoles, sustituidos.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
WO2011154725A3 (en) Compositions comprising buprenorphine
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
TN2012000248A1 (en) Novel spiropiperidine compounds
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MY173846A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
WO2010049449A3 (en) Novel salts of sunitinib
WO2011050054A3 (en) Coumarin compounds as receptor modulators with therapeutic utility
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
TN2013000425A1 (en) Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
MX2010008490A (es) Triazolopiridazinas como inhibidores de par1, su produccion y su uso como medicamentos.
MX2012013362A (es) Una composicion farmaceutica de liberacion controlada de losartan.

Legal Events

Date Code Title Description
FG Grant or registration